Literature DB >> 33246091

Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics.

Susi Zhu1, Yeye Guo2, Xu Zhang2, Hong Liu2, Mingzhu Yin2, Xiang Chen3, Cong Peng4.   

Abstract

Pyruvate kinase M2 (PKM2), a key rate-limiting enzyme of glycolysis, is a critical regulator in tumor metabolism. PKM2 has been demonstrated to overexpressed in various cancers and promoted proliferation and metastasis of tumor cells. The errant expression of PKM2 has inspired people to investigate the function of PKM2 and the therapeutic potential in cancer. In addition, some studies have shown that the upregulation of PKM2 in tumor tissues is associated with the altered expression of lncRNAs and the poor survival. Therefore, researchers have begun to unravel the specific molecular mechanisms of lncRNA-mediated PKM2 expression in cancer metabolism. As the tumor microenvironment (TME) is essential in tumor development, it is necessary to identify the role of PKM2 in TME. In this review, we will introduce the role of PKM2 in different cancers as well as TME, and summarize the molecular mechanism of PKM2-related lncRNAs in cancer metabolism. We expect that this work will lead to a better understanding of the molecular mechanisms of PKM2 that may help in developing therapeutic strategies in clinic for researchers.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Agonists; Inhibitors; Long noncoding RNA; Pyruvate kinase M2; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33246091     DOI: 10.1016/j.canlet.2020.11.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

Review 1.  Targeting Energy Metabolism in Cancer Treatment.

Authors:  Joanna Kubik; Ewelina Humeniuk; Grzegorz Adamczuk; Barbara Madej-Czerwonka; Agnieszka Korga-Plewko
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  Expression and clinical significance of pyruvate kinase M2 in breast cancer: A protocol for meta-analysis and bioinformatics validation analysis.

Authors:  Huayan Li; Min Yan; Xiaoyong Wu; Yanliang Wang; Lin Huang
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

3.  PD-1 Targeted Nanoparticles Inhibit Activated T Cells and Alleviate Autoimmunity via Suppression of Cellular Energy Metabolism Mediated by PKM2.

Authors:  Zhangluxi Liu; Jing Xu; Hongxi Li; Jia Shu; Guannan Su; Chunjiang Zhou; Peizeng Yang
Journal:  Int J Nanomedicine       Date:  2022-04-13

Review 4.  The Role of PKM2 in Diabetic Microangiopathy.

Authors:  Chao Tu; Liangzhi Wang; Lan Wei
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-04       Impact factor: 3.249

5.  Identification of a Three-Glycolysis-Related lncRNA Signature Correlated With Prognosis and Metastasis in Clear Cell Renal Cell Carcinoma.

Authors:  Tinghao Li; Hang Tong; Junlong Zhu; Zijia Qin; Siwen Yin; Yan Sun; Xudong Liu; Weiyang He
Journal:  Front Med (Lausanne)       Date:  2022-01-10

Review 6.  circRNAs: Insight Into Their Role in Tumor-Associated Macrophages.

Authors:  Saili Duan; Shan Wang; Tao Huang; Junpu Wang; Xiaoqing Yuan
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

7.  LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.

Authors:  Feifei Pu; Jianxiang Liu; Doudou Jing; Fengxia Chen; Xin Huang; Deyao Shi; Wei Wu; Hui Lin; Lei Zhao; Zhenhao Zhang; Xiao Lv; Baichuan Wang; Zhicai Zhang; Zengwu Shao
Journal:  Int J Oncol       Date:  2022-03-04       Impact factor: 5.650

8.  Mogroside V Improves Follicular Development and Ovulation in Young-Adult PCOS Rats Induced by Letrozole and High-Fat Diet Through Promoting Glycolysis.

Authors:  Lan'e Huang; Aihong Liang; Tianlong Li; Xiaocan Lei; Xi Chen; Biyun Liao; Jinru Tang; Xiting Cao; Gang Chen; Fengyu Chen; Yiyao Wang; Linlin Hu; Weiguo He; Meixiang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-28       Impact factor: 5.555

9.  ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.

Authors:  Wenjing Yang; Beili Wang; Qian Yu; Te Liu; Tong Li; Tongtong Tian; Anli Jin; Lin Ding; Wei Chen; Hao Wang; Jingrong Xian; Baishen Pan; Jian Zhou; Jia Fan; Xinrong Yang; Wei Guo
Journal:  Theranostics       Date:  2022-08-21       Impact factor: 11.600

Review 10.  Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.

Authors:  Soghra Bagheri; Mahdie Rahban; Fatemeh Bostanian; Fatemeh Esmaeilzadeh; Arash Bagherabadi; Samaneh Zolghadri; Agata Stanek
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.